Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 8/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559688 | 0.99 | MEN1 (0.48) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5559685 | 0.99 | MEN1 (0.48) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5560116 | 0.90 | MAPT (0.47) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5566225 | 0.90 | MAPT (0.47) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5560113 | 0.90 | MAPT (0.47) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5559830 | 0.88 | MAPT (0.49) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5564776 | 0.88 | MAPT (0.49) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5559832 | 0.88 | MAPT (0.49) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5566698 | 0.88 | MEN1 (0.46) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL5564771 | 0.88 | MEN1 (0.46) | MEN1LMNAGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | claimed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | claimed |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | MEN1 2929/4885LMNA 2762/4885GAA 269/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | MEN1 2929/4885LMNA 2762/4885GAA 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.